Anktiva (nogapendekin alfa inbakicept) + BCG
ImmunityBio (IBRX)
Decision dateJan 6, 2027
52 days away
Marketer take
A label expansion into papillary-only BCG-unresponsive NMIBC would widen the urologist audience for an existing brand and push competing bladder-sparing therapies to sharpen patient-selection messaging.
- Sponsor company
- ImmunityBio (IBRX)
- Indication
- BCG-unresponsive NMIBC with papillary disease without CIS (sBLA)
- Therapeutic area
- Oncology, Urology
- Event
- PDUFA target action date
- Date
- Jan 6, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?